FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068475242> ?p ?o ?g. }

• W2068475242 endingPage "978" @default.
• W2068475242 startingPage "S" @default.
• W2068475242 abstract "Background: Patients with HCV and cirrhosis represent a population in most need of treatment; however, with interferon and ribavirin (RBV)-based therapy, such patients had been more difficult to treat and cure and are often underrepresented in clinical trials. Ledipasvir/sofosbuvir (LDV/SOF) phase 2 and 3 studies included >500 patients with compensated cirrhosis. We analyzed the overall efficacy and safety, and further evaluated the impact of baseline HCV NS5A resistance associated variants (RAVs) on sustained virologic response in a population of HCV infected patients with cirrhosis. Methods: Treatment-naive or treatment-experienced patients with chronic HCV genotype 1 (GT1) infection and compensated cirrhosis who had participated in phase 2 or 3 studies and had received LDV/SOF +/RBV for 12 or 24 weeks were included in this pooled analysis. Results: Five hundred thirteen subjects with compensated cirrhosis were identified. The majority (91%) of patients had cirrhosis diagnosed by biopsy or fibroscan (>12.5 kPa). Of the 292 patients on whom a fibroscan was performed, 137/292 (47%) had a value >20 kPa. The majority were treatmentexperienced (353, 69%), male (342, 67%), GT1a (306, 60%), and IL28B non-CC (405, 79%). Two hundred forty patients (68% of the treatment- experienced patients) had previously received a protease inhibitor-containing regimen. One hundred thirteen (22%) initiated therapy with a baseline platelet count of <100,000 cells/μL. Sixty-three (12%) initiated therapy with a baseline albumin <3.5 g/dL. The patients received one of four regimens: 12 weeks of LDV/SOF (118, 23%), or LDV/SOF+RBV (204, 40%), or 24 weeks of LDV/SOF (133, 26%) or LDV/SOF+RBV (58, 11%). Overall, 96% (493/513) achieved SVR12. Among treatment-experienced patients, 12 weeks of LDV/SOF resulted in a 90% SVR rate, while adding RBV or extending treatment duration increased this rate to ≥96%. With a 1% cutoff, 94/511 (18%) cirrhotic patients were identified as having BL NS5A RAVs. SVR results by regimen and patient group and the effect of baseline NS5A RAVs on SVR will be presented. Safety in patients with cirrhosis was similar to that previously reported in patients without cirrhosis. Adverse events including anemia were more frequent in patients who received RBV. No other trends in adverse events or serious adverse events were noted. Conclusions: Based on these results, LDV/SOF is effective, safe, and well-tolerated for the treatment of HCV GT1 infection in patients with compensated cirrhosis. LDV/SOF regimens for 12 and 24 weeks were efficacious in treatment-naive cirrhotic patients with baseline HCV NS5A RAVs. High SVR rates were also achieved among treatment-experienced patients with cirrhosis when RBV was added to 12 weeks of LDV/SOF or when treatment was extended to 24 weeks." @default.
• W2068475242 created "2016-06-24" @default.
• W2068475242 creator A5001405064 @default.
• W2068475242 creator A5010140648 @default.
• W2068475242 creator A5013141366 @default.
• W2068475242 creator A5014652609 @default.
• W2068475242 creator A5019949529 @default.
• W2068475242 creator A5027618515 @default.
• W2068475242 creator A5029936292 @default.
• W2068475242 creator A5034244372 @default.
• W2068475242 creator A5039066540 @default.
• W2068475242 creator A5039624341 @default.
• W2068475242 creator A5045504446 @default.
• W2068475242 creator A5045967483 @default.
• W2068475242 creator A5046885231 @default.
• W2068475242 creator A5049864482 @default.
• W2068475242 creator A5054201295 @default.
• W2068475242 creator A5064179616 @default.
• W2068475242 creator A5070817587 @default.
• W2068475242 creator A5075322332 @default.
• W2068475242 creator A5088683463 @default.
• W2068475242 creator A5088842832 @default.
• W2068475242 date "2015-04-01" @default.
• W2068475242 modified "2023-09-25" @default.
• W2068475242 title "364 An Integrated Safety, Efficacy, and Virology Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin" @default.
• W2068475242 doi "https://doi.org/10.1016/s0016-5085(15)33341-2" @default.
• W2068475242 hasPublicationYear "2015" @default.
• W2068475242 type Work @default.
• W2068475242 sameAs 2068475242 @default.
• W2068475242 citedByCount "0" @default.
• W2068475242 crossrefType "journal-article" @default.
• W2068475242 hasAuthorship W2068475242A5001405064 @default.
• W2068475242 hasAuthorship W2068475242A5010140648 @default.
• W2068475242 hasAuthorship W2068475242A5013141366 @default.
• W2068475242 hasAuthorship W2068475242A5014652609 @default.
• W2068475242 hasAuthorship W2068475242A5019949529 @default.
• W2068475242 hasAuthorship W2068475242A5027618515 @default.
• W2068475242 hasAuthorship W2068475242A5029936292 @default.
• W2068475242 hasAuthorship W2068475242A5034244372 @default.
• W2068475242 hasAuthorship W2068475242A5039066540 @default.
• W2068475242 hasAuthorship W2068475242A5039624341 @default.
• W2068475242 hasAuthorship W2068475242A5045504446 @default.
• W2068475242 hasAuthorship W2068475242A5045967483 @default.
• W2068475242 hasAuthorship W2068475242A5046885231 @default.
• W2068475242 hasAuthorship W2068475242A5049864482 @default.
• W2068475242 hasAuthorship W2068475242A5054201295 @default.
• W2068475242 hasAuthorship W2068475242A5064179616 @default.
• W2068475242 hasAuthorship W2068475242A5070817587 @default.
• W2068475242 hasAuthorship W2068475242A5075322332 @default.
• W2068475242 hasAuthorship W2068475242A5088683463 @default.
• W2068475242 hasAuthorship W2068475242A5088842832 @default.
• W2068475242 hasConcept C126322002 @default.
• W2068475242 hasConcept C159047783 @default.
• W2068475242 hasConcept C2522874641 @default.
• W2068475242 hasConcept C2775999097 @default.
• W2068475242 hasConcept C2777214474 @default.
• W2068475242 hasConcept C2778390639 @default.
• W2068475242 hasConcept C2780040827 @default.
• W2068475242 hasConcept C3020491458 @default.
• W2068475242 hasConcept C71924100 @default.
• W2068475242 hasConcept C90924648 @default.
• W2068475242 hasConceptScore W2068475242C126322002 @default.
• W2068475242 hasConceptScore W2068475242C159047783 @default.
• W2068475242 hasConceptScore W2068475242C2522874641 @default.
• W2068475242 hasConceptScore W2068475242C2775999097 @default.
• W2068475242 hasConceptScore W2068475242C2777214474 @default.
• W2068475242 hasConceptScore W2068475242C2778390639 @default.
• W2068475242 hasConceptScore W2068475242C2780040827 @default.
• W2068475242 hasConceptScore W2068475242C3020491458 @default.
• W2068475242 hasConceptScore W2068475242C71924100 @default.
• W2068475242 hasConceptScore W2068475242C90924648 @default.
• W2068475242 hasIssue "4" @default.
• W2068475242 hasLocation W20684752421 @default.
• W2068475242 hasOpenAccess W2068475242 @default.
• W2068475242 hasPrimaryLocation W20684752421 @default.
• W2068475242 hasRelatedWork W2138093122 @default.
• W2068475242 hasRelatedWork W2341282998 @default.
• W2068475242 hasRelatedWork W2793060991 @default.
• W2068475242 hasRelatedWork W2883638265 @default.
• W2068475242 hasRelatedWork W2883924450 @default.
• W2068475242 hasRelatedWork W2897919916 @default.
• W2068475242 hasRelatedWork W3037168713 @default.
• W2068475242 hasRelatedWork W3092499120 @default.
• W2068475242 hasRelatedWork W3112349584 @default.
• W2068475242 hasRelatedWork W4308131156 @default.
• W2068475242 hasVolume "148" @default.
• W2068475242 isParatext "false" @default.
• W2068475242 isRetracted "false" @default.
• W2068475242 magId "2068475242" @default.
• W2068475242 workType "article" @default.